Below we review moves from smid-cap biopharma companies during January 2022. See Table 1 for monthly moves for companies and categories on BPIQ.com compared to XBI. Table 1. BPIQ company January 2022 moves
Highlights for January 2022
Biggest positive monthly move
$FUSN: +83% Announced research collaborations with Pepscan, 48Hour Discovery, and AstraZeneca
Biggest negative monthly move
$ALGS: -73.1% At beginning of year announced halting ALG-010133 further developments
January Big Movers biggest moves
$XERS +20% when RECORLEV was approved
$CRIS -28% when Phase 1/2 data reported from CA-4948 trial for AML/MDS
Additional big moves in January 2022
$MOLN +30%; positive Ensovibep Phase 2 results
$BCRX +28%; preliminary ORLADEYO net revenue
$ADMP +27%; submitted Fast Track application
$GMDA +23%; Omidubicel BLA submission update
$EVFM +23%; record net sales
$EWTX +23%; positive EDG-5506 Phase 1b results
$ANNX -24%; promising Phase 2 data (but high rate of discontinuation)
$GRTS -42%; positive CORAL-BOOST first cohort data
$ALGS -56.7%; ALG-010133 developments halted
Highlights for February 2022
$FGEN will respond to FDA meeting about roxadustat during quarterly report
$ICPT Ocaliva Phase 3 data in trials for cirrhosis or fibrosis due to NASH
Keep an eye out in the next few weeks for fourth quarter reports from a majority of the companies in our database including commercial product sales
See our Big Movers post for Big Movers/Suspected Movers in February
Komentáre